Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

NCT07152756 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests how stopping the medication semaglutide for one week affects stomach emptying and the clarity of the stomach lining during an endoscopy in adults with delayed stomach emptying.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 418 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2028-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07152756 ↗

Description as written by the study sponsor.

A prospective, single-center, observational study to compare the risk of gastric retention and endoscopic mucosal visibility between the exposure group (one-week discontinuation of semaglutide before EGD) and non-exposure group (no semaglutide use before EGD)

Treatments tested

Esophagogastroduodenoscopy Procedure

Assess the gastric retention and the endoscopic mucosal visibility score during esophagogastroduodenoscopy

Main thing measured	Rate of gastric retention
Sponsor	Fudan University
Conditions studied	Gastric Retention
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07152756 ↗